{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:24:23Z","timestamp":1779161063189,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"9911","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","thelancet.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/s0140-6736(13)61719-5","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T21:50:28Z","timestamp":1380750628000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1795,"title":["Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial"],"prefix":"10.1016","volume":"383","clinical-trial-number":[{"clinical-trial-number":"nct00917384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01170663","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Charles S","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Tomasek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cho Jae","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Dumitru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Passalacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanchal","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Safran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Vieira","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustapha","family":"Tehfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eldar","family":"Topuzov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Raymond","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choondal","family":"Sivanandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Pikiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minori","family":"Koshiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astra M","family":"Liepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(13)61719-5_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/S0140-6736(13)61719-5_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004064.pub3","article-title":"Chemotherapy for advanced gastric cancer","volume":"3","author":"Wagner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S0140-6736(13)61719-5_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0959-8049(02)00013-8","article-title":"Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model","volume":"38","author":"Jung","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0140-6736(13)61719-5_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5009\/gnl.2009.3.2.88","article-title":"The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer","volume":"3","author":"Kim","year":"2009","journal-title":"Gut Liver"},{"key":"10.1016\/S0140-6736(13)61719-5_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1245\/s10434-007-9596-0","article-title":"Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients","volume":"15","author":"Lieto","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/S0140-6736(13)61719-5_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3748\/wjg.v8.i4.591","article-title":"Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer","volume":"8","author":"Song","year":"2002","journal-title":"World J Gastroenterol"},{"key":"10.1016\/S0140-6736(13)61719-5_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000111118","article-title":"Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival","volume":"72","author":"Cabuk","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/S0140-6736(13)61719-5_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2004.00.3467","article-title":"Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma","volume":"24","author":"Juttner","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(13)61719-5_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.bjc.6605483","article-title":"Biomarkers of angiogenesis and their role in the development of VEGF inhibitors","volume":"102","author":"Murukesh","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/S0140-6736(13)61719-5_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1471-2407-8-123","article-title":"Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer","volume":"8","author":"Oh","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/S0140-6736(13)61719-5_bib11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1634\/theoncologist.2010-0387","article-title":"Targeting angiogenesis in esophagogastric adenocarcinoma","volume":"16","author":"Okines","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/S0140-6736(13)61719-5_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/1471-2407-10-659","article-title":"Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-\u03b2 phosphorylation, and microvessel density in gastric cancer","volume":"10","author":"Suzuki","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/S0140-6736(13)61719-5_bib13","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.3748\/wjg.v12.i47.7598","article-title":"Microvessel density is a prognostic marker of human gastric cancer","volume":"12","author":"Zhao","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/S0140-6736(13)61719-5_bib14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(13)61719-5_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0140-6736(13)61719-5_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0140-6736(13)61719-5_bib18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/biomet\/69.3.661","article-title":"Asymmetric group sequential boundaries for monitoring clinical trials","volume":"69","author":"DeMets","year":"1982","journal-title":"Biometrika"},{"key":"10.1016\/S0140-6736(13)61719-5_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(13)61719-5_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(13)61719-5_bib21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","article-title":"Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone","volume":"30","author":"Kang","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(13)61719-5_bib22","doi-asserted-by":"crossref","unstructured":"Ford H, Marshall A, Wadsley J, et al. Cougar-02: a randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. 10th Annual Gastrointestinal Cancer Symposium; San Francisco, CA; Jan 24\u201326, 2013. LBA4.","DOI":"10.1200\/jco.2013.31.4_suppl.lba4"},{"key":"10.1016\/S0140-6736(13)61719-5_bib23","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2014a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0140-6736(13)61719-5_bib24","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(13)61719-5_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(13)61719-5_bib26","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1200\/JCO.2011.40.3774","article-title":"Targeting the hepatocyte growth factor-cMET axis in cancer therapy","volume":"30","author":"Blumenschein","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(13)61719-5_bib27","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1002\/cncr.25893","article-title":"Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45","volume":"117","author":"Li","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(13)61719-5_bib28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/gutjnl-2012-302039","article-title":"A systematic approach to therapeutic target selection in oesophago-gastric cancer","volume":"62","author":"Paterson","year":"2013","journal-title":"Gut"},{"key":"10.1016\/S0140-6736(13)61719-5_bib29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mc.20516","article-title":"Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer","volume":"48","author":"Seto","year":"2009","journal-title":"Mol Carcinog"},{"key":"10.1016\/S0140-6736(13)61719-5_bib30","doi-asserted-by":"crossref","first-page":"e17687","DOI":"10.1371\/journal.pone.0017687","article-title":"Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer","volume":"6","author":"Song","year":"2011","journal-title":"PloS One"},{"issue":"suppl","key":"10.1016\/S0140-6736(13)61719-5_bib31","doi-asserted-by":"crossref","first-page":"LBA4000","DOI":"10.1200\/jco.2012.30.18_suppl.lba4000","article-title":"A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3)","volume":"30","author":"Waddell","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673613617195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673613617195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T08:24:37Z","timestamp":1539332677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673613617195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":30,"journal-issue":{"issue":"9911","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0140673613617195"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(13)61719-5","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(13)61719-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(13)61892-9","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}